Collaborations

Arguably one of the most important challenges facing the pharma industry today is the efficient adoption of digital platforms to improve the discovery and development of new medicines. At Bayer, we have tackled this challenge with widespread digitalization efforts across our R&D organization, based on the firm belief that we must evolve in order to

Like many things in life, early-stage drug discovery is a numbers game. The more chemical space that can be explored earlier in the discovery process, the greater the likelihood of finding novel, biologically active molecules that meet key parameters for clinical advancement.

When NVIDIA invented the graphics processing unit (GPU) back in the 1990s, it wasn’t just a breakthrough — it was a revolution. GPUs were originally intended to improve computer graphics. They certainly did that, but more realistic video games were just the start.

In 2017, Takeda and Schrödinger joined forces to accelerate the discovery of novel, differentiated therapeutic compounds using Schrödinger’s physics-based computational platform, and having access to Takeda’s deep, innovative expertise and experience in drug discovery.

In 2017, Takeda and Schrödinger joined forces to accelerate the discovery of novel, differentiated therapeutic compounds using Schrödinger’s physics-based computational platform, and having access to Takeda’s deep, innovative expertise and experience in drug discovery.

In late 2019, Schrödinger and AstraZeneca teamed up with the aim of accelerating the discovery of novel therapeutic compounds by improving the throughput of binding affinity predictions.